15 December 2025
15 December 2025
The framework has had a lukewarm reaction, with trade association EFPIA saying the policies are “not strong enough”.
The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.
Daybue Stix will become available in limited quantities from the first quarter of 2026.
Sobi will make an upfront cash payment of $950m.
Propelled by a flurry of dealmaking late in the year, M&As in 2025 ended on a strong note, with high activity expected to continue in 2026.
The NMPA’s decision is supported by data from the ATLAS Phase III trials.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
